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this modulation is usually assessed by the well-known study 
of heart rate variability (HRV), which means an analysis of 
spontaneous and induced fluctuations that occur in HR 
(or in the electrocardiographic RR interval) as a result of 
ANS sympathetic and parasympathetic activities on sinus 
node automaticity.
Most patients with diabetic polyneuropathy (PNP) show 
some degree of autonomic dysfunction. Patients with 
predominant autonomic signs and symptoms are considered 
as having diabetic autonomic neuropathy (DAN). Although 
this may affect any organ system, it usually starts in the 
skin neurovascular system (foot microcirculation) and in 
the cardiovascular system (CAN). Furthermore, it affects 
the gastrointestinal system (gastroparesis, constipation and 
diarrhea) and genitourinary system (urinary incontinence, 
neurogenic bladder and erectile dysfunction). 
CAN is one of the major complications of DM since its 
presence is associated with worsening prognosis and patient’s 
poorer life quality. The following clinical manifestations are 
associated with CAN: resting tachycardia, severe orthostatic 
hypotension (OH), syncope, exercise intolerance (due to 
chronotropic and inotropic response block), perioperative 
instability, asymptomatic myocardial ischemia and infarction, 
left ventricular (LV) diastolic and systolic dysfunction, and 
increased risk of renal diseases, chronic renal failure (CRF), 
stroke, and sudden cardiac death (SCD). 
Despite the potential negative impact on the quality of 
life of patients with CAN, this disease falls among the least 
understood and least frequently diagnosed complications 
of individuals with DM. This type of neuropathy can usually 
be found in approximately 25% of the patients with type-1 
diabetes mellitus (DM1) and in 34% of those with type-2 
diabetes mellitus (DM2). The prevalence of CAN progressively 
increases in a direct proportion to age, duration of DM and 
poor glycemic control1.
CAN may be subdivided into subclinical (in which functional 
and reversible alterations are predominant) and clinical (when 
structural neuronal alterations are already present): the first 
one is only diagnosed by tests and may occur as soon as the 
diagnosis of certain types of DM are diagnosed, or in the first 
years of the disease; the second form, as the name suggests, 
is symptomatic and occurs in more advanced stages2. 
Autonomic fibers are compromised in the several clinical 
subtypes of diabetic neuropathies. The most common type 
(classical PNP: symmetric, distal, and predominantly sensitive), 
shows a strong correlation between the progressive lesion of 
both somatic and autonomic fibers, i.e., nowadays we know 
that 50% of the diabetic patients with PNP have asymptomatic 
Summary
Cardiovascular autonomic neuropathy (CAN) is one of 
the most clinically significant complications of diabetes 
mellitus (DM), but one of the least frequently diagnosed. 
In this review, we discuss the major risk factors for the 
development and progression of CAN in patients with DM, 
the natural history of autonomic neuropathy and its impact 
on cardiovascular disease in DM, as well as the tests for the 
early diagnosis and staging of CAN in the clinical practice. The 
bibliographic research was based on two databases: Medline 
and Tripdatabase, with the following descriptors: diabetic 
cardiovascular autonomic neuropathy and cardiovascular 
autonomic neuropathy and diabetes. We selected English 
and German articles, written between 1998 and 2007. In its 
initial stages (early and intermediate), CAN may be diagnosed 
and reversed. However, in advanced cases (severe stage), the 
only treatment that remains is a symptomatic one. CAN is 
associated with higher cardiovascular morbidity and mortality 
rates and poor quality of life in diabetic individuals.
Introduction
Cardiovascular autonomic neuropathy (CAN) occurs 
when peripheral autonomic fibers (sympathetic and 
parasympathetic) of the cardiovascular system (CVS), 
are affected, thus resulting in neurohumoral regulation 
disturbances. The sympathetic-vagal balance (both tonic 
and phasic) modulates the function of three of the main CVS 
structures: the sinus node (heart rate), the ventricles (end-
systolic and end-diastolic volumes) and the blood vessels, 
including microcirculation (total peripheral resistance). 
The autonomic nervous system (ANS), thus, plays a key 
role in the modulation of the CVS dynamics by means of 
an interaction between the sympathetic and vagal tonus 
which, in physiologic conditions, act in a negative feedback 
manner. In other words, the activation of the former is 
followed by the inhibition of the latter. In clinical practice, 
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CAN, whereas 100% of those with symptomatic CAN present 
classical PNP3,4. 
This review is aimed at finding and discussing the best 
evidence available in the recent literature (from 1998 to 2007) 
in order to clarify three key questions:
1) Which are the major risk factors (RF) for the development 
and progression of CAN in individuals with DM? Is there any 
difference between CAN of DM1 and that of DM2?
2) What is CAN natural history and its clinical impact on DM 
or, in practical terms, what is the significance of this diagnosis 
for both physician and diabetic patient?
3) How should an early diagnosis and staging be made in 
the clinical practice, and which are currently the best tests in 
terms of specificity, sensitivity and reproducibility?
For this purpose, the following strategy was used: 
bibliographic survey in two databases (Medline and 
Tripdatabase) with the descriptors diabetic cardiovascular 
autonomic neuropathy and cardiovascular autonomic 
neuropathy and diabetes. We selected articles written in 
English and German from 1998 to 2007 (a total of 106 
references). Nevertheless, articles published before 1998 
were also included, provided  they were relevant or had been 
frequently cited (19 references). 
Risk factors for CAN development and 
progression in patients with diabetes 
mellitus. Differences between CAN in DM1 
and in DM2
The risk of developing autonomic dysfunction in DM depends 
on several factors. However, two of them are well established in 
the literature and are common to both DM1 and DM2: Duration 
of disease and the degree of glycemic control2,5-7. In both DM 
types, poor blood glucose control (chronic hyperglycemia) 
plays an important role both in the initial pathophysiology 
(oxidative stress, microcirculation dysfunction due to nitric 
oxide loss and Schwann cell lesion due to accumulation of 
free radicals) as well as in its progression (axonal degeneration 
and neuronal apoptosis)8-10. Although diabetic neuropathies 
are classified among DM microangiopathic complications, 
the pathophysiological mechanism is multifactorial, and 
there is enough evidence that small-fiber PNP and even CAN 
may precede DM (PNP related to glucose intolerance or 
prediabetes)19. Although it falls outside the scope of this review, 
the final common pathway of the different mechanisms already 
described to explain the pathophysiology of PNP seems to be 
oxidative and nitrative stress4,9.
The presence of CAN, however, is not only associated with 
the duration and degree of hyperglycemia. In the past years, 
several studies6,11-15 consistently showed that cardiovascular 
risk factors (CVRF), such as systolic blood pressure (SBP), 
body mass index (BMI), triglycerides, and smoking, play an 
important role in the development of CAN. It is noteworthy 
that these factors share at least two points in common: they 
are potentially modifiable and are associated with insulin 
resistance, once again suggesting that CAN may arise with a 
metabolic syndrome. 
Even more important, however, were the results of 
the Steno 2 study, in which the intensified multifactorial 
intervention (hyperglycemia, hypertension,  dyslipidemia and 
microalbuminuria) in patients with DM2 reduced the risk of 
CAN progression by 68%13,14. The role of intensive control 
(three doses of NPH insulin) in preventing and slowing the 
progression of CAN in patients with DM1 is also well-known: 
in the classical DCCT study, its prevalence was reduced by 
53%16.
Regarding the differences between CAN in DM1 and in 
DM2, it is worth pointing out that both signs and symptoms 
appear later in DM1 than in DM2, i.e., the great majority of 
DM1 patients with CAN remain totally asymptomatic for years 
and, when the symptoms appear, CAN is usually in advanced 
and irreversible stages17.
CAN seems to be more prevalent in DM2 patients, 
appearing earlier and causing higher mortality rates 8,18. 
This is likely due to the longer duration of the metabolic 
abnormalities (dysglycemia), which occur even prior to the 
diagnosis of DM2, in the prediabetes and metabolic syndrome 
stages19,20. These differences suggest that the natural history 
of CAN presents different progression routes in DM1 and in 
DM2, and moreover, that pathophysiological mechanisms also 
seem to be different. During the past decade, several studies 
demonstrated that anti-sympathetic ganglion, anti-vagus nerve 
or anti-myelin-associated-glycoprotein autoantibodies occurr 
in a significant proportion of patients with DM1, and many of 
them presented severe CAN21. 
Also worthy of attention is the fact that CAN symptoms are 
inexplicably uncommon and, when present, they oscillate and 
do not always progress, as is the case with OH. As a matter 
of fact, the great majority of diabetic patients with CAN are 
currently known to remain asymptomatic for decades, and less 
than 1% develops symptomatic OH1,2. Since clinical history 
and physical examination are ineffective for its early detection, 
it is of crucial importance to perform quantitative tests in order 
to diagnose CAN in its initial and still reversible stages22.
In the past two decades, there was a great advance in our 
knowledge of RF for CAN initiation and progression, thanks 
to the development of more sensitive and specific methods 
for its diagnosis. It is the case of the HRV study, which 
allows a non-invasive, selective and longitudinal assessment 
of autonomic function by mathematically analyzing the 
magnitude of HR variations23. 
In DM2, the following RF are associated with a reduced HRV: 
age, obesity, hyperinsulinemia, DM duration, hypertension, 
retinopathy, PNP and smoking1,2,24,25. In DM1, the factors 
that increase the risk of developing CAN are: HbA1c, SBP, 
age, retinopathy, albuminuria, PNP, hypertriglyceridaemia, 
dyslipidemia, gender (female), and time of exposure to 
hyperglycemia6,11,26-28.
Current data that differentiate CAN in DM1 and in DM2 
in terms of risk factors and natural history are summarized 
in Table 1. We can conclude that, in relation to RF, there 
are modest differences between CAN in DM1 and in DM2 
and, regarding its natural history, CAN seem to progress more 
rapidly in DM2 than in DM1.
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Table 1 - CAN in DM1 and DM2: differences in relation to risk factors 
and natural history
Risk factors Type-I DM Type-II DM 
Age + +
Gender (female) + -
Obesity - +
Hyperinsulinemia na +
Duration of DM ++ ++
Smoking + +
HbA1c ++ ++
Hypertension ++ +
Retinopathy ++ +
Hypertrygliceridemia + +
Classical PNP ++ ++
Microalbuminuria ++ ++
Dyslipidemia (> LDL and < HDL) + (+)
Natural history
Prevalence at diagnosis of DM 7.7% 5%
Prevalence after 10 years 38% 65%
Prevalence (random) 25% 34%
Strong association: ++; moderate: +; not found: -; controversial: (+); na: not 
applicable; inverse association: 1/+.
and without CAN were reviewed in this meta-analysis. During 
the follow-up period, which ranged from 0.5 to 16 years, 
mortality rates were consistently higher in patients with CAN 
(30%) than in those without CAN (13%). However, a major 
criticism currently directed to all of these studies is the fact 
that coronary artery disease (CAD) frequently coexists with 
CAN in diabetic patients, thus CAN may not actually be the 
single factor accounting for higher cardiovascular mortality 
in DM43. Currently there is strong evidence that CAN is an 
independent risk factor for CV mortality in diabetic patients44, 
and it has already been demonstrated that patients with CAN 
associated with liver diseases and alcohol use (non-diabetic 
individuals) also present a higher mortality risk45. 
The mechanisms proposed to account for this increased 
mortality are: difficulty in recognizing angina (atypical 
manifestations such as nausea, shortness of breath and 
tiredness are common), asymptomatic ischemia or MI, 
dysfunction of the coronary flow autoregulation, increased 
heart rate, LV systolic and diastolic dysfunction, increased risk 
of arrhythmias (prolonged QT interval), decreased nocturnal 
protection against MI, changes in BP circadian cycle, increased 
cardiac mass, increased risk of microalbuminuria and, lastly, 
apnea1,2. The death in bed syndrome, in which the triad 
CAN + sympathetic-adrenergic discharge + nocturnal 
hypoglycemia plays a key role, is also well-known46.
Several clinical studies42,43,47,48 suggest an important 
participation of CAN in the etiopathogenesis of asymptomatic 
myocardial ischemia (AMI) found in diabetic individuals. In 
a large prospective study47, 434877 patients with MI were 
evaluated, and 33% of them did not present chest pain. 
The percentages of patients with DM were 32.6% among 
those without chest pain, vs 25.4% in the group with chest 
pain. Moreover, several studies have shown an independent 
association between CAN and asymptomatic CAD49-51. 
Recently, AMI was found to be an independent predictor 
of hard CV events (SCD and MI) in asymptomatic type-2 
diabetic patients52.
On the contrary, in a recent review article53, a researcher 
raised an old controversy: the accelerated atherosclerosis seen 
in diabetics patients, and not CAN, would be responsible for 
the higher incidence of asymptomatic ischemia and infarction. 
Either way, both hypotheses are compatible with a third 
possibility: that CAN may exert a direct effect in accelerating 
even further46 the atherosclerotic process in DM.
In fact, there is currently both experimental and clinical 
evidence that peripheral arteries undergoing sympathectomy 
present severe atherosclerosis (macroangiopathy), due to a 
double mechanism: 
1) Hemodynamic effect - in which the faster systolic volume 
ejection itself (resulting from the resting tachycardia seen in 
CAN) is independently associated with vascular lesion53,54.
2) Phenotypic effect - greater migration of vascular 
smooth muscle cells (medium layer) to the inner layer and 
further differentiation of these cells, regardless of nitric 
oxide activity55. 
In a recent prospective study56,57 for detecting the prevalence 
and predictors of silent coronary disease in patients with DM2, 
the strongest predictor of a positive pharmacological stress 
Natural history of cardiovascular autonomic 
neuropathy and its impact on diabetes 
mellitus cardiovascular disease
Although the natural history of CAN in DM remains partially 
obscure, great advances, regarding its prognosis, have been 
achieved in the past decade. Despite difficulties such as the 
lack of standardization and of a single methodology in the 
diagnosis among the different epidemiological studies, the 
prevalence of CAN is known to range from 7.7% in patients 
with newly diagnosed DM1 (although this can be related to 
transient hemodynamic changes) to 90% in DM1 patients 
eligible for pancreas transplantation2. 
A Finnish study29 followed patients with DM2 for ten years 
and found that the prevalence of CAN, as assessed by HRV, 
increased from 5% to 65%, whereas in the control group 
(non-diabetic patients) it increased from 2% to 28%. The 
prevalence of OH, in turn, (SBP decrease by 20mmHg or 
more after three minutes in the standing position) increased, 
after ten years, from 7% to 24% in the group studied (DM2), 
and from 6% to 9% in the control group. Additionally, the 
presence of CAN after five years was an independent risk 
factor for stroke30,31.
Since early 1980’s, several studies had already been 
demonstrating increased mortality in diabetic patients with 
CAN, as can be observed in Table 25,7,29,32-41. However, only in a 
recent meta-analysis42 a strong association between the degree 
of autonomic dysfunction and death risk was established. 
Fifteen studies involving a total of 2900 diabetic patients with 
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Table 2 - Mortality in diabetic patients with (CAN+) and without (CAN-) cardiovascular autonomic neuropathy
Authors Ref. Follow-up (years) Number of tests
Mortality
P valueNAC+ NAC-
n % n %
Ewing et al (1980) 5 5 3+S 21/40 53 5/33 15 <0.05
Hasslacher et al (1983) 32 5 1 3/16 19 3/42 7 NS
Navarro et al (1990) 33 3.3 (1 – 7.3) 2 41/175 23 2/57 4 <0.05
Sampson et al (1990) 7 10 1+S 18/49 37 4/38 11 <0.05
O’Brien et al (1991) 34 5 4 23/84 27 21/422 5 <0.05
Ewing et al (1991) 35 3 5+QTc 10/32 31 3/39 8 <0.05
Jermendy et al (1991) 36 5 4+QTc 12/30 40 1/23 4 <0.05
Rathmann et al (1993) 37 8 2+QTc 8/35 23 1/35 3 <0.05
Luft et al (1993) 38 8 (6 – 10) 4 7/34 21 1/19 5 NS
Navarro et al (1996) 39 1 – 11.5 2 101/359 28 6/128 5 <0.05
Orchard et al (1996) 40 2 1 8/88 9 9/399 2 <0.05
Töyry et al (1996) 29 10 1 3/23 13 3/99 3 <0.05
Veglio et al (2000) 41. 5 2+QTc 10/76 13 10/240 4 <0.05
Total Mean: 5 – 265/1041 25 69/1574 4  – 
NS - non significant; Qtc - corrected QT interval; S - autonomic symptoms; Ref. - reference.
(adenosine) myocardial perfusion imaging (SPECT) was the 
presence of CAN (assessed by the abnormal Valsalva ratio). 
This study also revealed that 22% (n = 113) of the patients 
with type-2 diabetes already presented AMI at enrollment. 
The CVRF were then more intensively treated in these patients 
(statins, aspirin and angiotensin-converting enzyme inhibitors), 
and after three years 71 of them underwent a repeat stress 
imaging which demonstrated resolution of the myocardial 
ischemia in 79% (n = 56)57.
By showing a significant correlation between the severity 
of CAN and the degree of impairment of the left ventricular 
function, other studies using Doppler echocardiography 
suggested that CAN plays an important role in the pathogenesis 
of diabetic cardiomyopathy. LV diastolic dysfunction, in 
particular, seems to occur early and be asymptomatic in young 
diabetic individuals with CAN58.
Finally, there is a well established association between 
CAN and diabetic nephropathy which contributes to the 
high mortality rates found in diabetic patients8. Ewing et al5 
reported a mortality rate of 53% after five years in a cohort 
of diabetic patients with CAN, vs 15% in the control group 
(diabetic patients without CAN). However, the individuals 
in the first group had long-standing symptomatic CAN and 
already presented macroangiopathy. As a matter of fact, 50% 
died of CRF. Sampson et al7, in turn, excluded diabetic patients 
with CRF or with clinical CAN for more than two years  from 
their cohort and found, during the follow-up period a mortality 
rate of 27% vs 11% in the control group (diabetic patients 
without CAN) after a period of 10 to 15 years. 
Lurbe et al59 correlated nondipping of nocturnal BP (due to 
a loss of the circadian rhythm of blood pressure that typically 
occurs in diabetic patients with CAN) with higher incidence 
of nephropathy (microalbuminuria) and macroangiopathy. 
Interestingly, in this study the increased SBP during sleep 
(nondippers) preceded the development of microalbuminuria 
in young type-1 diabetic individuals, thus linking CAN (earlier) 
to the deterioration in glomerular filtration rate (later). 
Tests for the early detection and staging of 
cardiovascular autonomic neuropathy in 
current clinical practice
For the diagnosis and staging of CAN in  clinical practice, 
noninvasive autonomic tests that are, simple, reproducible 
and sensitive both for the sympathetic (later impairment) and 
parasympathetic (earlier impairment) systems, should be used, 
so as to allow a longitudinal follow-up of the alterations23,60,61. 
There are currently two standardized methods for this 
purpose:
Ewing tests5,62
Of the five tests for outpatients classically described by 
Ewing62, three (deep breathing test, Valsalva maneuver and 
orthostatic test) are currently recommended by the American 
Diabetes Association and American Academy of Neurology8,61 
for DM2 at the time of diagnosis, and for DM1 five years 
after the diagnosis. After the first survey, these tests should be 
yearly repeated. These three tests have a good reproducibility, 
specificity higher than 91% and sensitivity from 93% (deep 
breathing and orthostatic test) to 98% (Valsalva).
Computerized heart rate variability (hrv) study1,2,8 
In the past years, earlier detection of autonomic 
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dysfunction63,64 became feasible thanks to the spectral analysis 
study of HRV. This modern technology uses a mathematical 
algorithm (fast Fourier transform) to turn a complex biological 
signal, such as HRV (result of the sympathovagal balance in 
the sinus node), into its causing components, presenting them 
according to the frequency with which they alter the HR2,23. 
The result (spectral amplitude) is presented in an Amplitude (Y 
axis) vs Frequency (X axis) diagram as shown in Figure 1A. We 
can observe that the spectral amplitude does not only reflect 
the magnitude of HRV (Y axis), but also the oscillations in 
different frequencies, i.e., the number of HR fluctuations per 
second (X axis). This allows us to better distinguish the relative 
impact of the sympathetic and vagal modulation on HRV.  
It has been demonstrated that the total spectral amplitude 
(total power or TP) of HRV consists of three key frequency 
bands, as represented in Figure 1:
1) very low-frequency component or VLF (from 0.01 to 
0.04 Hz) which is related to fluctuations in the vasomotor 
tonus linked to thermoregulation and sweating (sympathetic 
control); 
2) low-frequency component or LF (from 0.04 to 0.15 
Hz) associated with the baroreflex (sympathetic control with 
vagal modulation);
3) high-frequency component or HF (from 0.15 to 0.5 
Hz) which is related to sinus arrhythmia (parasympathetic 
control). 
In diabetic patients with predominantly vagal (but early) 
dysfunction, HF amplitude is reduced or absent, whereas 
in the presence of predominantly sympathetic (but late) 
dysfunction, LF and VLF amplitudes are reduced. The more 
advanced cases are characterized by the absence of all 
frequency bands. In addition to its high sensitivity (99%) and 
specificity (100%), this method2,23,62-65 has the advantage of not 
requiring active cooperation from the patient (it is performed 
at rest). However, it requires computerized equipment and 
coupled mathematical software.
Currently, seven parameters are used for the early detection 
of CAN: the three spectral analysis frequency bands (VLF, LF 
and HF) plus four Ewing tests (the three previously described 
plus the OH test described in Attachment 1).  
The protocol presented at the end of this review, in 
Figure 1A - Spectral power of a 52-year-old female patient with DM2 for 12 months and CAN+.
VLF LF HF
Parameter Normal values Patient value
TP, ms2 4,484 to 2,448 182
VLF, ms2 1,684 to 525 118
LF, ms2 1,586 to 754 21
HF, ms2 1,178 to 772 42,2
TP - total spectral power; HF - high frequency band; LF - low frequency band; VLF 
- very low frequency band.
Attachment 1, is based on recommendations of different 
ANS study laboratories10,24,28,63-65, as well as on European and 
American consensus1,2,23,60,61. According to this protocol, the 
diagnosis of CAN is made when at least three of the seven tests 
are abnormal with a specificity of 100%. On the other hand, 
when only two tests are abnormal, the diagnosis of incipient 
CAN is made with a specificity of 98%1,2.
In the absence of a computerized system for HRV spectral 
analysis, the four Ewing tests should be performed. The 
diagnosis of established CAN requires at least two abnormal 
tests. When only one of them is abnormal (usually the deep 
breathing test or the orthostatic one), the diagnosis of early or 
incipient CAN is made. Later, with the progression of CAN, the 
Valsalva maneuver also becomes abnormal, characterizing the 
diagnosis of intermediate CAN. Finally, when OH is present, 
severe CAN is diagnosed1,2,8.
Deep breathing (or E:I), and orthostatic tests (or 30:15 
ratio) as well as spectral analysis in the HF band assess only the 
parasympathetic component (vagal afference of the heart) of 
cardiovascular ANS which is the most precociously affected in 
DM (Notice that, although the patient does not present CAN, 
the HF band in Figure 1B is already abnormal). The spectral 
amplitude in VLF band and the OH test, in turn, assess the 
sympathetic component of the ANS. The LF band spectral 
power and the Valsalva maneuver assess both the sympathetic 
and parasympathetic components of  CV autonomic function, 
and are the most sensitive.
Conclusions
Although CAN is the most extensively studied and the 
most hazardous among the clinical manifestations of diabetic 
autonomic neuropathy, its pathophysiology remains one of the 
most obscure and controversial topic in current diabetology. 
For instance, some researchers consider CAN an additional 
component of metabolic syndrome19,20,66. Several questions 
remain unanswered, such as: 
1) What are the mechanisms responsible for triggering 
early CAN and where is the point of no return, i.e., the point 
from which morphological and pathophysiological alterations 
become irreversible? 
2) What is the best method to detect silent coronary disease 
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in diabetic individuals67, and when should it be performed?
3) What is the relationship between hyperinsulinemia68, 
CAN and metabolic syndrome? Which comes first: 
parasympathetical dysfunction or insulin resistance69?  
It is fundamental to point out that CAN is currently known 
as an early complication of DM, and its progression, both 
insidious and silent, is associated with considerable morbidity 
and mortality, as well as with serious impairment of the quality 
of life of diabetic individuals. 
Objective detection of CAN in its early stages (incipient and 
intermediate forms) via CV tests and computerized systems 
(spectral analysis of HRV) is both feasible and mandatory in 
the current state of art for four reasons: 
1) Since CAN may be delayed (DCCT and Steno 2 studies), 
and since nowadays there is a real possibility of reverting 
its natural course, the early diagnosis and staging of CAN 
is crucial, in order to stop further progression to advanced 
and irreversible stages (severe CAN). Moreover, all studies on 
clinical treatment show that incipient or intermediate CAN 
may be reverted or improved, whereas severe cases cannot 
be either reverted or improved 1,70.
2) Symptomatic manifestations occur very late in the course 
of DM and do not always progress. This stresses the importance 
of quantifying autonomic deficit by means of objective and 
prospective tests, i.e., diagnosis should not be made only on 
the basis of clinical history or physical examination. 
3) The more severe CAN is (late stages), the higher CV 
risk and mortality seems to be71, since we now know that, 
once the symptoms develop, mortality in five to seven years 
is of the order of 50%5. In addition, CAN is a marker of poor 
prognosis for microangiopathy, especially nephropathy, as 
demonstrated by a prospective Swedish study with an eleven-
year follow-up72. Therefore, early detection and staging may 
identify diabetic individuals at risk for silent CAD, CHF, CRF 
and premature death. It is fundamental to warn and alert 
these patients when they initiate to physical training and 
exercise programs. 
4) Timely identification of DM autonomic dysfunction 
may improve the prophylaxis of target-organ injury – both 
macroangiopathy (CAD, SCD and stroke) and microangiopathy 
(CRF and retinopathy), with the use of specific drugs for the 
CVRF associated with CAN: hypertension and albuminuria 
(ACE inhibitors and angiotensin II receptor blockers) and 
dyslipidemia (statins). A more intensive control of DM and 
hypertension in individuals with incipient and intermediate 
CAN is also currently recommended70,73.
No less important is the fact that, in the past years, we 
have learned that the CVRF traditionally associated with 
macroangiopathy in DM2 (BMI, triglycerides, smoking 
and SBP) also play a pathophysiological role in the natural 
history of microangiopathic complications of DM1, in 
particular CAN11,26. Even more interestingly, the intensive 
treatment of these factors prevents the progression of CAN 
in DM213,14.
In conclusion, the presence of CAN in diabetic patients is 
associated with a mortality rate, caused by CV events, two to 
three times higher, and total mortality rate up to five times 
higher in relation to diabetic patients without CAN74. Thus, 
CAN is an important risk marker for macroangiopathy, in 
general, and for CAD, in particular.
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Figure 1B - Spectral power of a 34-year-old patient with DM1 for 23 years and using continuous insulin infusion pump for eight years.
Parameter Normal values Patient value
TP, ms2 4,484 to 2,448 2,658
VLF, ms2 1,684 to 525 895
LF, ms2 1,586 to 754 1,085
HF, ms2 1,178 to 772 678
TP - total spectral power; HF - high frequency band; LF - low frequency band; VLF 
- very low frequency band.
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Attachment 1
Protocol for yearly CAN screening of the Universidade 
Federal de São Paulo (UNIFESP).
A) Questionnaire for symptoms
A.1) When standing up: dizziness, visual disorders, 
presyncope.
A.2) When exercising: shortness of breath, nausea, 
diaphoresis, pain.
A.3) Dysphagia, nausea, early satiety, anorexia.
A.4) Diarrhea, fecal incontinence, constipation, postprandial 
vomiting.
A.5) Sexual dysfunction: erectile, vaginal lubrication.
A.6) Incontinence, pollakiuria, urgency, retention, recurrent 
UTI.
A.7) Anhidrosis, hyperhidrosis, heat intolerance, gustatory 
sweating.
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B) Seven parameters
B.1) Valsalva Maneuver (Valsalva ratio)
The patient remains in the supine position (SP) at 30 
degrees and, after a 15-minute rest, forcibly exhales to keep a 
40-mmHg pressure for 15 seconds. At approximately the 14th 
second, the patient shows a peak physiological tachycardia. 
After this effort, the sphygmomanometer valve is released and 
the patient is monitored by EKG tracing for 30 to 45 seconds, 
when a peak physiological bradycardia occurs. The Valsalva 
ratio is the relation between tachycardia and bradycardia or 
between the longest and shortest RR intervals. 
B.2) Orthostatic test (30:15 ratio)
The test consists of performing EKG with the patient in 
SP under the same conditions as described above. After 
the patient stands up (orthostasis), the relation between the 
heart rates or between the RR-intervals corresponding to the 
maximum tachycardia at approximately the 15th beat and 
the maximum bradycardia at approximately the 30th beat 
is analyzed. 
B.3) Deep breathing test (E:I ratio)
The test consists of performing EKG during deep inspiration 
and expiration with a minimum duration of 5 seconds each 
and obtaining the maximum heart rate (inspiration) divided by 
the minimum heart rate (expiration), or longest RR (E) divided 
by the shortest RR (I) ratio.
B.4) Orthostatic hypotension test (OH)
Patient in SP at 30 degrees for a 15-minute rest. Blood pressure 
is measured at baseline and three minutes after standing. A drop 
in systolic blood pressure higher than or equal to 20 mmHg 
is considered abnormal and a drop in systolic blood pressure 
between 10 and 19 mmHg is considered borderline. 
B.5) Spectral analysis of HRV (spectral amplitude in the 
three bands: VLF, LF and HF)
Patient at rest in SP at 30 degrees and breathing 
spontaneously. The ECG is recorded in a computer or laptop 
for 300 seconds and is further analyzed by a mathematical 
algorithm and expressed in a diagram of oscillation amplitude 
(HR variations per second) vs frequency (hertz). 
Figures 1A and 1B show the three frequency bands, from 
left to right: VLF, LF and HF of the spectral amplitude. The 
values expressed in square milliseconds reflect the area under 
the curve of each band (green, blue, and red, respectively). 
Note
All CV tests should be performed in the morning, under fasting 
conditions, with a capillary blood glucose level lower than 180 mg/
dl and all cardiovascular medication, anxiolytics, antidepressants, 
caffeine and decongestants discontinued for at least eight hours 
and optimally 24 hours before (because it will depend on the 
half-life of each drug in particular). Normal values always depend 
on the age range of the patient and are standardized23,65. 
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